MASH vs. MASLD: Which Medications Are Actually FDA Approved for Weight Loss? | Dr Mauricio Gonzalez
Dr. Mauricio Gonzalez clarifies that the United States has two FDA-approved medications specifically for MASH (metabolic dysfunction-associated steatohepatitis): resmetirom and semaglutide (Wegovy). However, for pure MASLD (metabolic dysfunction-associated fatty liver disease) without inflammation, there are currently no FDA-approved medications.
Summary
The transcript addresses the distinction between FDA-approved medications for different stages of metabolic liver disease. Dr. Gonzalez explains that there is often confusion about whether GLP-1 medications are prescribed specifically for liver disease or whether their liver benefits are secondary to treating type 2 diabetes or obesity. He clarifies the current FDA approval landscape: For MASH, which represents the more advanced, inflammatory stage of metabolic liver disease, two medications have received FDA approval. Resmetirom is described as a thyroxine receptor agonist that works in the liver and was the first medication to receive FDA approval for this indication. Semaglutide, marketed as Wegovy for weight loss, also has FDA approval for MASH. In contrast, for pure MASLD—the earlier stage characterized by fatty liver without significant inflammation—there are currently no FDA-approved medications available in the United States. This distinction is important for clinical practice and patient expectations regarding treatment options.
Key Insights
- Resmetirom was the first FDA-approved medication specifically for MASH, functioning as a thyroxine receptor agonist in the liver
- Semaglutide (Wegovy) has received FDA approval for MASH in addition to its obesity and diabetes indications
- There are currently no FDA-approved medications specifically for pure MASLD without the inflammatory component
- The United States has exactly two FDA-approved medications for MASH as of the time of this discussion
- The distinction between MASLD and MASH is clinically significant because medication approvals differ based on disease stage
Topics
Transcript
[0:00] Can you prescribe GLP-1s for MASLD or is the prescription for a type 2 diabetes or obesity and it has that effect on MASLD? >> In the United States, we have two medications that are FDA-approved for MASLD and MASH. For MASH, we have resmetirom and this is basically like an agonist of thyroxine receptor in the liver that was the first FDA-approved medication for that. Semaglutide, Wegovy, has FDA approval for MASH. For MASLD though, we don't, for pure MASLD. [0:30] But for MASH, we have these two medications.
Full transcript available for MurmurCast members
Sign Up to AccessMore from The Proof with Simon Hill
How Effective Are Weight Loss Drugs? The Risk and Limitations You Should Know About | EP#422
GLP-1 weight loss drugs are significantly more effective than diet alone, with 90-95% of clinical trial participants losing weight, but real-world non-response rates reach 20%. However, discontinuation rates are high (75% within 18 months), and without proper nutrition and exercise support, users risk losing up to 40% muscle mass while regaining primarily fat, creating sarcopenic obesity.
What Is the MIND Diet? (You Don't Have to Eat Perfectly) | Dr Terry Simpson
The MIND diet combines Mediterranean and DASH diets, focusing on increased fruits, vegetables, legumes, whole grains, and healthy fats while reducing red meat. Dr. Simpson emphasizes that perfection isn't required—studies show people scoring around 12.5 out of 15 points experienced the most benefits.
How Does HeartFlow's AI Analyze Your Heart Scan? | Dr Campbell Rogers | EP#426
Dr. Campbell Rogers explains HeartFlow's AI analysis process for heart scans, emphasizing that the company assesses image quality first, rejecting approximately 2-3% of scans that are too fuzzy. He highlights that scanner type, procedure techniques, and medications used at each site significantly impact image quality and the ability to track disease progression over time.
Muscle Loss Fix: Why Movement Beats More Protein | Simon Hill
Protein is often overemphasized in discussions about muscle loss, but the real driver of sarcopenia in America is sedentary lifestyle and lack of resistance training stimulus. Most people consume sufficient protein; the limiting factor is movement and strength training, not dietary protein intake.
How Does Gila Monster Unlocked the Study of Weight Loss Medication | Dr Federica Amati | EP#427
Scientists discovered that Gila monsters, which eat rarely and move slowly, naturally produce exceptionally high levels of GLP-1, a hormone that suppresses hunger and slows nutrient absorption. This biological adaptation allows these reptiles to survive extended periods without eating, and this discovery led to the development of GLP-1-based weight loss medications.